Loxo Oncology, Inc. 4
4 · Loxo Oncology, Inc. · Filed Jan 12, 2017
Insider Transaction Report
Form 4
AISLING CAPITAL III LP
10% Owner
Transactions
- Purchase
Common Stock
2017-01-10$31.00/sh+160,000$4,960,000→ 4,188,920 total
Footnotes (1)
- [F1]The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.